{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:46:08Z","timestamp":1785905168105,"version":"3.56.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The efficacy of conversion therapy for gastric cancer with peritoneal metastasis (P1) and\/or positive peritoneal lavage cytology (CY1) treated with immunotherapy remains unclear. This study aimed to clarify clinical outcomes in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this retrospective, single-institution cohort study, 144 patients with P1 and\/or CY1 confirmed by staging laparoscopy at initial diagnosis received first-line immunotherapy with chemotherapy and\/or trastuzumab between November 2019 and March 2024. Patients were divided into a conversion therapy group and a palliative therapy group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of 144 patients, 75 showed a clinical response and underwent second-look laparoscopy. Negative peritoneal metastasis and cytology were confirmed in 36 patients, all of whom underwent conversion surgery. Compared with the palliative group, the conversion group had significantly longer median progression-free survival (22.9\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 5.8 months;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001) and overall survival (33.4\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 12.3 months;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001). Among those who had surgery, 27 patients (75.0%, 27\/36) achieved R0 resection (complete resection with no residual tumor). Patients with peritoneal cancer index \u22642 had a significantly longer median overall survival than those with peritoneal cancer index &gt;2 (not reached\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 28.5 months;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.006). No serious treatment-related adverse events led to treatment discontinuation or death.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Conversion surgery following immunochemotherapy provided a significant survival benefit for gastric cancer patients with P1 and\/or CY1. When immunochemotherapy is effective, active staging laparoscopy should be performed to assess surgical feasibility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000004095","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T03:00:08Z","timestamp":1780542008000},"page":"2346-2355","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Conversion surgery after immunotherapy and chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology: A retrospective cohort study"],"prefix":"10.1097","volume":"139","author":[{"given":"Huayuan","family":"Liang","sequence":"first","affiliation":[{"name":"Department of General Surgery and Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China"},{"name":"Department of Gastrointestinal Surgery, Cancer Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing 102218, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailun","family":"Huang","sequence":"additional","affiliation":[{"name":"Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaihua","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rou","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Cancer Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing 102218, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"R1-20260805","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1097\/CM9.0000000000003277","article-title":"Burden of digestive system diseases in China and its provinces during 1990\u20132019: Results of the 2019 global disease burden study","volume":"137","author":"Cheng","year":"2024","journal-title":"Chin Med J"},{"key":"R2-20260805","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/CM9.0000000000003140","article-title":"Socioeconomic inequalities in cancer incidence and mortality: An analysis of GLOBOCAN 2022","volume":"137","author":"Cao","year":"2024","journal-title":"Chin Med J"},{"key":"R3-20260805","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s10120-012-0182-1","article-title":"Treatment outcomes of systemic chemotherapy for peritoneal carcinomatosis arising from gastric cancer with no measurable disease: Retrospective analysis from a single center","volume":"16","author":"Hong","year":"2013","journal-title":"Gastric Cancer"},{"key":"R4-20260805","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","article-title":"Peritoneal carcinomatosis from gastric cancer: A multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy","volume":"17","author":"Glehen","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 1","key":"R5-20260805","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s10120-016-0684-3","article-title":"Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings","volume":"20","author":"Ishigami","year":"2017","journal-title":"Gastric Cancer."},{"key":"R6-20260805","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1245\/s10434-022-11582-5","article-title":"Safety and efficacy of intraperitoneal paclitaxel plus intravenous fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for gastric cancer with peritoneal metastasis","volume":"29","author":"Kang","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"R7-20260805","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.3390\/cancers11111715","article-title":"Conversion surgery with HIPEC for peritoneal oligometastatic gastric cancer","volume":"11","author":"Mielko","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R8-20260805","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10120-019-00994-0","article-title":"Conversion therapy for peritoneal lavage cytology-positive type 4 and large type 3 gastric cancer patients selected as candidates for R0 resection by diagnostic staging laparoscopy","volume":"23","author":"Yasufuku","year":"2020","journal-title":"Gastric Cancer"},{"key":"R9-20260805","article-title":"Efficacy and safety of conversion therapy by intraperitoneal and intravenous paclitaxel plus oral S-1 in gastric cancer patients with peritoneal metastasis: A prospective phase II study","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"R10-20260805","doi-asserted-by":"crossref","first-page":"5388","DOI":"10.1200\/JCO.23.00170","article-title":"Health-related quality of life with Nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric\/gastroesophageal junction cancer or esophageal adenocarcinoma from CheckMate 649","volume":"41","author":"Moehler","year":"2023","journal-title":"J Clin Oncol"},{"key":"R11-20260805","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"issue":"Supplement 5","key":"R12-20260805","article-title":"LBA53 sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study","volume":"32","author":"Xu","year":"2021","journal-title":"Ann Oncol"},{"key":"R13-20260805","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"R14-20260805","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"R15-20260805","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat Res"},{"key":"R16-20260805","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"key":"R17-20260805","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1038\/s41467-021-25188-0","article-title":"Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer","volume":"12","author":"Cascone","year":"2021","journal-title":"Nat Commun"},{"key":"R18-20260805","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00464-017-5673-z","article-title":"Diagnostic staging laparoscopy in gastric cancer: A prospective cohort at a cancer institute in Japan","volume":"32","author":"Irino","year":"2018","journal-title":"Surg Endosc"},{"key":"R19-20260805","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10120-012-0156-3","article-title":"Long-term follow-up of patients who were positive for peritoneal lavage cytology: Final report from the CCOG0301 study","volume":"15","author":"Kodera","year":"2012","journal-title":"Gastric Cancer"},{"key":"R20-20260805","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s10147-017-1128-8","article-title":"The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy","volume":"22","author":"Kano","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"R21-20260805","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1245\/ASO.2005.03.065","article-title":"The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection","volume":"12","author":"Bentrem","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"R22-20260805","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1245\/s10434-010-1362-z","article-title":"7th edition of the AJCC cancer staging manual: Stomach","volume":"17","author":"Washington","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"R23-20260805","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s10120-017-0749-y","article-title":"Prognostic significance of peritoneal lavage cytology in staging gastric cancer: Systematic review and meta-analysis","volume":"21","author":"Jamel","year":"2018","journal-title":"Gastric Cancer"},{"key":"R24-20260805","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/01.sla.0000143245.28656.15","article-title":"Patterns of initial recurrence in completely resected gastric adenocarcinoma","volume":"240","author":"D\u2019Angelica","year":"2004","journal-title":"Ann Surg"},{"key":"R25-20260805","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/gutjnl-2024-333617","article-title":"CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases","volume":"74","author":"Li","year":"2024","journal-title":"Gut"},{"key":"R26-20260805","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.3390\/jcm10235666","article-title":"Intraperitoneal chemotherapy as adjuvant or perioperative chemotherapy for patients with type 4 scirrhous gastric cancer: PHOENIX-GC2 trial","volume":"10","author":"Ishigami","year":"2021","journal-title":"J Clin Med"},{"key":"R27-20260805","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/bjs.4637","article-title":"Therapeutic strategy for signet ring cell carcinoma of the stomach","volume":"91","author":"Kunisaki","year":"2004","journal-title":"Br J Surg"},{"key":"R28-20260805","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/SLA.0000000000001793","article-title":"Differential prognostic implications of gastric signet ring cell carcinoma: Stage adjusted analysis from a single high-volume center in Asia","volume":"265","author":"Chon","year":"2017","journal-title":"Ann Surg"},{"key":"R29-20260805","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10120-018-0860-8","article-title":"Clinicopathological differences in signet ring cell adenocarcinoma between early and advanced gastric cancer","volume":"22","author":"Kao","year":"2019","journal-title":"Gastric Cancer"},{"key":"R30-20260805","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdy540","article-title":"Safety and efficacy of nivolumab in combination with S-1\/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (ATTRACTION-4)","volume":"30","author":"Boku","year":"2019","journal-title":"Ann Oncol"},{"key":"R31-20260805","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"R32-20260805","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ejca.2013.09.024","article-title":"Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases","volume":"50","author":"Elias","year":"2014","journal-title":"Eur J Cancer"},{"key":"R33-20260805","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s11605-014-2477-5","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: Outcomes from a single tertiary institution","volume":"18","author":"Tabrizian","year":"2014","journal-title":"J Gastrointest Surg"},{"key":"R34-20260805","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1007\/s10120-019-00969-1","article-title":"The efficacy of treatment options for patients with gastric cancer and peritoneal metastasis","volume":"22","author":"Rau","year":"2019","journal-title":"Gastric Cancer"},{"key":"R35-20260805","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1200\/JCO.18.00364","article-title":"PHOENIX-GC trial: Underpowered for significant results?","volume":"37","author":"Li","year":"2019","journal-title":"J Clin Oncol"},{"key":"R36-20260805","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.ejso.2019.03.011","article-title":"Downstaging of lymph node metastasis after neoadjuvant intraperitoneal and systemic chemotherapy in gastric carcinoma with peritoneal metastasis","volume":"45","author":"Hao","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"R37-20260805","doi-asserted-by":"crossref","first-page":"e70054","DOI":"10.1002\/ctm2.70054","article-title":"Single-cell characterization of differentiation trajectories and drug resistance features in gastric cancer with peritoneal metastasis","volume":"14","author":"Peng","year":"2024","journal-title":"Clin Transl Med"},{"key":"R38-20260805","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"R39-20260805","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/gutjnl-2018-318070","article-title":"Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response","volume":"69","author":"Wang","year":"2020","journal-title":"Gut"},{"key":"R40-20260805","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1200\/jco.2016.34.4_suppl.81","article-title":"A phase II study of neoadjuvant chemotherapy with a modified FOLFOX6 regimen for locally advanced gastric cancer","volume":"34","author":"Wang","year":"2016","journal-title":"J Clin Oncol"},{"key":"R41-20260805","doi-asserted-by":"crossref","first-page":"927781","DOI":"10.3389\/fonc.2022.927781","article-title":"Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial","volume":"12","author":"Guo","year":"2022","journal-title":"Front Oncol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000004095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:01:23Z","timestamp":1785902483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000004095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":41,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000004095","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"2025-09-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}